Clinical Trial Update: The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Update on a Phase 2 clinical trial of tremelimumab, an anti-CTLA-4 antibody, in malignant mesothelioma, with the current trial status listed as UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Tremelimumab (tremelimumab)

Snippet

Sponsor: Azienda Ospedaliera Universitaria Senese | Conditions: Malignant Mesothelioma | Phase 2 | Status: UNKNOWN